Oncostatin M's Involvement in the Pathogenesis of Chronic Rhinosinusitis: Focus on Type 1 and 2 Inflammation

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Dec 23

PMID 38137445

Authors

Chie Ishikawa

Sachio Takeno

Yukako Okamoto

Tomohiro Kawasumi

Takashi Kakimoto

Kota Takemoto

Manabu Nishida

Takashi Ishino

Takao Hamamoto

Tsutomu Ueda

Akio Tanaka

Affiliations

Soon will be listed here.

Abstract

Objectives: The cytokine oncostatin M (OSM) elicits pathogenic effects involving disruption of the epithelial barrier function as a part of immunological response networks. It is unclear how these integrated cytokine signals influence inflammation and other physiological processes in the pathology of chronic rhinosinusitis (CRS). We investigated the expression and distribution of OSM and OSM receptor (OSMR) in CRS patients' sinonasal specimens, and we compared the results with a panel of inflammatory cytokine levels and clinical features.

Patients And Methods: We classified CRS patients as eosinophilic (ECRS, = 36) or non-eosinophilic (non-ECRS, = 35) based on the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis phenotypic criteria and compared their cases with those of 20 control subjects. We also examined OSM's stimulatory effects on cytokine receptor expression levels using the human bronchial epithelium cell line BEAS-2B.

Results: RT-PCR showed that the OSM mRNA levels were significantly increased in the CRS patients' ethmoid sinus mucosa. The OSM mRNA levels were positively correlated with those of TNF-α, IL-1β, IL-13, and OSMR-β. In BEAS-2B cells, OSM treatment induced significant increases in the OSMRβ, IL-1R1, and IL-13Ra mRNA levels.

Conclusions: OSM is involved in the pathogenesis of CRS in both type 1 and type 2 inflammation, suggesting the OSM signaling pathway as a potential therapeutic target for modulating epithelial stromal interactions.

References

Lund V, Kennedy D . Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl. 1995; 167:17-21. View

Fujieda S, Imoto Y, Kato Y, Ninomiya T, Tokunaga T, Tsutsumiuchi T . Eosinophilic chronic rhinosinusitis. Allergol Int. 2019; 68(4):403-412. DOI: 10.1016/j.alit.2019.07.002. View

Tomassen P, Vandeplas G, Van Zele T, Cardell L, Arebro J, Olze H . Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016; 137(5):1449-1456.e4. DOI: 10.1016/j.jaci.2015.12.1324. View

Jones S, Jenkins B . Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018; 18(12):773-789. DOI: 10.1038/s41577-018-0066-7. View

Kato A, Schleimer R, Bleier B . Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022; 149(5):1491-1503. PMC: 9081253. DOI: 10.1016/j.jaci.2022.02.016. View

Gearing D, Comeau M, Friend D, Gimpel S, Thut C, McGourty J . The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 1992; 255(5050):1434-7. DOI: 10.1126/science.1542794. View

Wang C, Lin H, Song Y, Hsu Y, Lin S, Hsu P . Protein kinase C-dependent growth-associated protein 43 phosphorylation regulates gephyrin aggregation at developing GABAergic synapses. Mol Cell Biol. 2015; 35(10):1712-26. PMC: 4405633. DOI: 10.1128/MCB.01332-14. View

Xu Z, Huang Y, Delemarre T, Cavaliere C, Zhang N, Bachert C . Advances in chronic rhinosinusitis in 2020 and 2021. J Allergy Clin Immunol. 2022; 149(3):854-866. DOI: 10.1016/j.jaci.2021.12.782. View

Pothoven K, Schleimer R . The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease. Tissue Barriers. 2017; 5(3):e1341367. PMC: 5571776. DOI: 10.1080/21688370.2017.1341367. View

10.

Fritz D, Kerr C, Fattouh R, Llop-Guevara A, Khan W, Jordana M . A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. J Immunol. 2010; 186(2):1107-18. DOI: 10.4049/jimmunol.0903476. View

11.

Gevaert P, Omachi T, Corren J, Mullol J, Han J, Lee S . Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020; 146(3):595-605. DOI: 10.1016/j.jaci.2020.05.032. View

12.

Pothoven K, Norton J, Suh L, Carter R, Harris K, Biyasheva A . Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease. J Allergy Clin Immunol. 2016; 139(6):1966-1978.e9. PMC: 5529124. DOI: 10.1016/j.jaci.2016.10.039. View

13.

Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H . Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015; 70(8):995-1003. PMC: 5032997. DOI: 10.1111/all.12644. View

14.

Le Goff B, Singbrant S, Tonkin B, Martin T, Romas E, Sims N . Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. Cytokine. 2014; 68(2):101-9. DOI: 10.1016/j.cyto.2014.04.001. View

15.

Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C . Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy. 2021; 77(1):186-196. PMC: 9290136. DOI: 10.1111/all.14906. View

16.

Pothoven K, Norton J, Hulse K, Suh L, Carter R, Rocci E . Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015; 136(3):737-746.e4. PMC: 4562861. DOI: 10.1016/j.jaci.2015.01.043. View

17.

Han J, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee S . Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021; 9(10):1141-1153. DOI: 10.1016/S2213-2600(21)00097-7. View

18.

Sofen H, Bissonnette R, Yosipovitch G, Silverberg J, Tyring S, Loo W . Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023; 57:101826. PMC: 9932343. DOI: 10.1016/j.eclinm.2023.101826. View

19.

Ishino T, Takeno S, Takemoto K, Yamato K, Oda T, Nishida M . Distinct Gene Set Enrichment Profiles in Eosinophilic and Non-Eosinophilic Chronic Rhinosinusitis with Nasal Polyps by Bulk RNA Barcoding and Sequencing. Int J Mol Sci. 2022; 23(10). PMC: 9146754. DOI: 10.3390/ijms23105653. View

20.

Tamura S, Morikawa Y, Miyajima A, Senba E . Expression of oncostatin M in hematopoietic organs. Dev Dyn. 2002; 225(3):327-31. DOI: 10.1002/dvdy.10156. View